Indication
For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Medicine details

Medicine name:
risankizumab (Skyrizi)
SMC ID:
SMC2196
Pharmaceutical company
AbbVie Ltd
BNF chapter
Skin
Submission type
Full
Status
Publication due date:
07 October 2019
SMC meeting date:
03 September 2019
Patient group submission deadline:
05 August 2019